Hong Kong Exchange Sees Surge in Listings for High-Growth Tech and Biotech Firms
Hong Kong reports a rise in growth-stage company listings, reaching 30% of the bourse following strategic regulatory reforms in AI and biotechnology sectors.
POLICY WIRE — Tokyo, Japan — Hong Kong’s financial markets are experiencing a notable influx of growth-oriented companies, according to Julia Leung, CEO of the Securities and Futures Commission. These firms, which prioritize high growth potential over immediate profitability, now account for 30% of the total bourse.
This figure represents a significant jump from the 10% share recorded in 2023. The shift follows a series of proactive regulatory reforms designed to attract early-stage enterprises specializing in artificial intelligence and biotechnology.
The city’s listing landscape underwent a structural transformation throughout 2025, highlighted by three primary trends: the growth of A + H dual listings and increased activity under Chapter 18A for biotech and Chapter 18C for specialist technology. These reforms have bolstered Hong Kong’s appeal by lowering market capitalization thresholds and permitting confidential filings.
In March 2026, the Hong Kong Exchanges & Clearing (HKEX) introduced a comprehensive overhaul of its listing framework. Described as the most extensive review of the exchange’s standards, the changes aim to expand eligibility while maintaining rigorous quality control.
The current strategy prioritizes institutional access to sectors like clean energy and AI, a move intended to stabilize valuations and limit retail exposure to volatile IPOs. This institutional shift is reflected in the city’s $22 billion fundraising momentum for 2025, with 30% of that capital originating from Chinese technology firms.
Reporting by Policy-Wire (PW)
